ArticleJournal of personalized medicine2021
Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial.
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).Journal of radiation research · 2023Trial
- Dosimetric and Clinical Impact of Bone Marrow-sparing Radiation Therapy for Anal Cancer: A Systematic Review.Advances in radiation oncology · 2026Review
- Feasibility of multi-energy CT and fat fraction MRI for characterizing active bone marrow response to pelvic external beam radiation therapy.Journal of applied clinical medical physics · 2026Article
- Innovative radiotherapy approaches.ESMO gastrointestinal oncology · 2026Review
- Optimising chemoradiotherapy in anal cancer.ESMO gastrointestinal oncology · 2026Review
- Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma.International journal of particle therapy · 2026Article
- Correlation between radiation dose to bone marrow subregions and acute hematologic toxicity inendometrial cancer treated with external beam radiotherapy.Clinical and translational radiation oncology · 2025Article
- The Influence of Pelvic Bone Dose-volume Parameters on Bone Marrow Suppression During Radiation Therapy in Patients With Stage I to III Rectal Cancer Based on Real-world Data.Advances in radiation oncology · 2025Article
- HPV-Related Cancers in Bosnia and Herzegovina: A Comprehensive Review.Acta medica academica · 2024Review
- Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review andClinical and translational radiation oncology · 2024Review
- Recent Advances in the Management of Anal Cancer.Healthcare (Basel, Switzerland) · 2023Review
- A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer.Cancers · 2022Article
- Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients.Frontiers in oncology · 2022Article
- A Pattern of Care Report on the Management of Patients with Squamous Cell Carcinoma of the Anus-A Study by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group.Medicina (Kaunas, Lithuania) · 2021Article
- Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.Radiation oncology (London, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the role of the selective avoidance of haematopoietically active pelvic bone marrow (BM), with a targeted intensity-modulated radiotherapy (IMRT) approach, to reduce acute hematologic toxicity (HT) in anal cancer patients undergoing concurrent chemo-radiation. We designed a one-armed two-stage Simon's design study to test the hypothesis that BM-sparing IMRT would improve by 20% the rate of G0-G2 (vs. G3-G4) HT, from 42% of RTOG 0529 historical data to 62% (α = 0.05; β = 0.20). A minimum of 21/39 (54%) with G0-G2 toxicity represented the threshold for the fulfilment of the criteria to define this approach as 'promising'. We employed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.